https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-14 / Clin. Dev. Immunol. 2011;2011:2675392011-09-14 00:00:002019-02-15 08:52:31Current immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-722011-08-31 00:00:002019-02-15 08:46:37Immunotherapy in human glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-26 / J. Leukoc. Biol. 2011 Nov;90(5):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-26 / J. Leukoc. Biol. 2011 Nov;90(5):951-622011-08-26 00:00:002019-02-15 09:17:19Differentiation of CD8+ T cells into effector cells is enhanced by physiological range hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-24 / Intervirology 2012;55(4):276-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-24 / Intervirology 2012;55(4):276-862011-08-24 00:00:002019-02-15 09:21:38Apoptin enhances the oncolytic properties of Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-402011-08-16 00:00:002019-02-15 08:50:07HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-852011-08-08 00:00:002019-02-15 08:52:48Immunotherapy for prostate cancer: biology and therapeutic approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-07 / J. Huazhong Univ. Sci. Technol. Med. Sci. 2011 Aug;31(4):488
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-07 / J. Huazhong Univ. Sci. Technol. Med. Sci. 2011 Aug;31(4):4882011-08-07 00:00:002011-08-07 00:00:00Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-04 / Ger Med Sci 2011;9:Doc18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-04 / Ger Med Sci 2011;9:Doc182011-08-04 00:00:002019-02-15 08:45:26Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-01 / Immunol. Res. 2011 Aug;50(2-3):235-47
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-01 / Immunol. Res. 2011 Aug;50(2-3):235-472011-08-01 00:00:002019-02-15 08:40:04Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)2011-07-31 11:54:532019-09-30 09:54:03Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
